The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in early 2025, and the grace periods for winding down compounding ended around May 2025
The main difference is that Retatrutide is a triple-agonist, targeting GLP-1, GIP, and the Glucagon receptors
pharmacovigilance experts are monitoring for adverse signals beyond clinical trials
For example, how did recovery progress during a previous bulk or training phase without the supplement in question
While current approved indications include obesity, type 2 diabetes, and cardio-renal complications, it is in the investigational space that we glimpse the future trajectory of this class: neurodegenerative diseases, systemic inflammatory conditions, psoriasis, hypertension, and type 1 diabetes
For someone who is looking for a supplement thats easy to incorporate into their day, these individually packaged supplements make it convenient to take on-the-go or travel with
